Pdt Partners, LLC Biocryst Pharmaceuticals Inc Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

A detailed history of Pdt Partners, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Pdt Partners, LLC holds 522,280 shares of BCRX stock, worth $3.95 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares

522,280

Previous 366,770 42.4%

Holding current value

$3.95 Million

Previous $2.27 Million 75.15%

% of portfolio

0.39%

Previous 0.23%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $996,819 - $1.35 Million	155,510 Added 42.4%	522,280 $3.97 Million
Q2 2024 Aug 15, 2024	SELL	$4.13 - $6.79 $56,799 - $93,382	-13,753 Reduced 3.61%	366,770 $2.27 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $338,999 - $530,336	69,325 Added 22.28%	380,523 $1.93 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $201,635 - $274,110	40,489 Added 14.96%	311,198 $1.86 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $480,637 - $567,309	71,630 Added 35.98%	270,709 $1.92 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $616,836 - $780,795	88,626 Added 80.24%	199,079 $1.4 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $393,609 - $586,944	49,573 Added 81.43%	110,453 $921,000
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $34,324 - $46,419	-3,269 Reduced 5.1%	60,880 $698,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $692,167 - $950,046	64,149 New	64,149 $808,000
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $296,756 - $478,444	-86,518 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $164,384 - $485,365	86,518 New	86,518 $412,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account